Regeneron announces primary endpoint met in Phase 3 QUASAR trial

Regeneron (REGN) Pharmaceuticals announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion, including those with central, branch and hemiretinal vein occlusions. In the trial, patients treated with EYLEA HD every 8 weeks experienced non-inferior vision gains compared to those treated with the approved monthly dosing regimen of EYLEA Injection 2 mg, the current standard of care. These data will be submitted to regulatory authorities around the world, with a submission to the U.S. Food and Drug Administration, FDA, planned for the first quarter of 2025, and are planned for presentation at an upcoming medical meeting.